We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva to Buy U.S. Rival Ivax for $7.4 Billion, Reclaim Top Generic Spot
Teva to Buy U.S. Rival Ivax for $7.4 Billion, Reclaim Top Generic Spot
July 25, 2005
It didn’t take long for Teva Pharmaceutical to return to its position as the world’s largest generic drugmaker. The Israeli company reclaimed the top spot with a splash, announcing plans July 25 to purchase U.S.-based Ivax — the world’s fourth largest generic firm — for $7.4 billion.